|
⚲
|
| Keyboard |
| Lynx1 Capital Management LP
✚
|
|
|---|---|
| CRD # | 310301 |
| SEC # | 801-127585 |
| CIK # | 0001910456 |
| AUM | 626.7 M (2026-03-31) |
| Employees | 5 (80% Investors, 0% Brokers) |
| Phone | 929-888-7476 |
| Address | D81 Calle C Dorado, PR 00646 |
| Source | [IAPD] [EDGAR] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Stoke Therapeutics Inc | 155.1 | ||
| GH Research PLC | 151.3 | ||
| Cullinan Oncology Inc | 127.4 | ||
| Agios Pharmaceuticals Inc | 88.3 | ||
| Denali Therapeutics Inc | 36.1 | ||
| C4 Therapeutics Inc | 18.4 | ||
| Frequency Therapeutics Inc | 17.4 | ||
| TScan Therapeutics Inc | 8.1 | ||
| Xencor Inc | 6.5 | ||
| Precision Biosciences Inc | 5.4 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Lynx1 Opportunity Fund I LP | 2023-03-03 | ||
| HF | Lynx1 Master Fund LP | [2021-10-13] | 114.0 M | 576.8 M |
| Filed 2025-05-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Commission $16,107 · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 626.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 5 | 626.7 |
| By Discretionary | ||
| Discretionary | 5 | 626.7 |
| Non-Discretionary | 0 | 0.0 |
| Total | 5 | 626.7 |
| By Non-United States Persons | ||
| Non-United States Persons | 159.1 | |
| United States Persons | 467.6 | |
| Total | 5 | 626.7 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Matt Auriemma | Director | 110 | 39 | |
| Wendy Beer | Director | 19 | 11 | |
| Weston Nichols | Director | 7 | 2 | |
| Lynx1 Capital Management LP | Promoter | 2 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001910456] | |
| 3 | [0001910456] | |
| 4 | [0001910456] | |
| SC 13D | [0001910456] | |
| SC 13G | [0001910456] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 5493003YH8Q5SHT17216 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Nichols Weston | |
| Passage Bio Inc | |
| Lynx1 Capital Management LP | |
| Korro Bio Inc | |
| TScan Therapeutics Inc | |
| Cullinan Therapeutics Inc | |
| Bionomics Limited/Fi |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
TScan Therapeutics Inc TCRX
Common Stock
|
2025-12-23 | Buy | 6,232 | $0.90 | 5,609 |
|
TScan Therapeutics Inc TCRX
Common Stock
|
2025-12-22 | Buy | 75,500 | $0.90 | 67,950 |
|
TScan Therapeutics Inc TCRX
"Common stock, $0.0001 par value per share (""Common Stock"")"
|
2025-12-19 | Buy | 80,069 | $0.90 | 72,062 |
|
Cullinan Therapeutics Inc CGEM
Common stock, $0.0001 par value per share
|
2025-10-28 | Buy | 165,667 | $8.40 | 1,391,603 |
|
Bionomics Limited/Fi NEUP
Common stock, $0.00001 par value per share
|
2025-10-21 | Buy | 639,110 | $5.14 | 3,285,025 |
|
Cullinan Therapeutics Inc CGEM
Common Stock
|
2025-10-17 | Buy | 32,217 | $7.84 | 252,581 |
|
Cullinan Therapeutics Inc CGEM
Common Stock
|
2025-10-16 | Buy | 150,000 | $8.86 | 1,329,000 |
|
Cullinan Therapeutics Inc CGEM
Common Stock
|
2025-10-15 | Buy | 51,500 | $7.94 | 408,910 |
|
Cullinan Therapeutics Inc CGEM
"Common stock, $0.0001 par value per share (""Common Stock"")"
|
2025-10-14 | Buy | 15,032 | $7.59 | 114,093 |
|
Cullinan Therapeutics Inc CGEM
Common Stock
|
2025-10-10 | Buy | 277,298 | $7.36 | 2,040,913 |
|
Cullinan Therapeutics Inc CGEM
Common Stock
|
2025-10-09 | Buy | 626,043 | $6.70 | 4,194,488 |
|
Cullinan Therapeutics Inc CGEM
"Common stock, $0.0001 par value per share (""Common Stock"")"
|
2025-10-08 | Buy | 556,300 | $6.46 | 3,593,698 |
|
Passage Bio Inc PASG
Common Stock
|
2025-07-24 | Buy | 66,423 | $5.71 | 379,275 |
|
Passage Bio Inc PASG
Common Stock
|
2025-07-23 | Buy | 49,302 | $5.74 | 282,993 |
|
Passage Bio Inc PASG
"Common stock, $0.0001 par value per share (""Common Stock"")"
|
2025-07-22 | Buy | 13,123 | $5.44 | 71,389 |
|
TScan Therapeutics Inc TCRX
Common Stock
|
2025-05-20 | Buy | 1,200,000 | $1.20 | 1,440,000 |
|
TScan Therapeutics Inc TCRX
"Common stock, $0.0001 par value per share (""Common Stock"")"
|
2025-05-19 | Buy | 1,388,794 | $1.20 | 1,666,553 |
|
Passage Bio Inc PASG
Common stock, $0.0001 par value per share
|
2024-12-27 | Buy | 373,645 | $0.65 | 242,869 |
|
TScan Therapeutics Inc TCRX
Pre-funded Warrant (right to buy) · derivative
|
2024-12-26 | Buy | 7,500,000 | $4.00 | 30,000,000 |
|
TScan Therapeutics Inc TCRX
Common Stock
|
2024-12-13 | Buy | 100,000 | $2.90 | 290,000 |
| showing 20 of 29 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
M37 Management LP
✚
|
CA | 656.4 M |
|
Altum Capital Management LLC
✚
|
NY | 647.8 M |
|
Standard General LP
✚
|
NY | 647.3 M |
|
Crow's Nest Holdings LP
✚
|
VA | 636.6 M |
|
Rose Park Advisors LLC
✚
|
MA | 629.9 M |
|
Manatuck Hill Partners LLC
✚
|
CT | 628.6 M |
|
Lago Asset Management LLC
✚
|
IL | 604.9 M |
|
Callodine Credit Management LLC
✚
|
MA | 603.0 M |
|
Endeavour Capital Advisors Inc
✚
|
CT | 602.7 M |
|
GFG Alternative Investment Advisors LLC
✚
|
CT | 599.6 M |